Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Mar;2(3):a006395.
doi: 10.1101/cshperspect.a006395.

Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease

Paul S Aisen  1 , Jeffrey Cummings, Lon S Schneider
Affiliations
Review

Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease

Paul S Aisen et al. Cold Spring Harb Perspect Med. 2012 Mar.

Abstract

In this work we consider marketed drugs for Alzheimer disease (AD) including acetylcholinesterase inhibitors (AChE-Is) and antiglutamatergic treatment involving the N-methyl-d-aspartate (NMDA) receptor. We discuss medications and substances available for use as cognitive enhancers that are not approved for AD or cognitive impairment, and other neurotransmitter-related therapies in development or currently being researched. We also review putative therapies that aim to slow disease progression by mechanisms not directly related to amyloid or tau.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Timeline of approved treatments for Alzheimer disease.
See this image and copyright information in PMC

References

    1. AD2000 Collaborative Group 2004. Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): Randomised double-blind trial. Lancet 363: 2105–2115 - PubMed
    1. Aisen PS, Davis KL, Berg JD, Schafer K, Campbell K, Thomas RG, Weiner MF, Farlow MR, Sano M, Grundman M, et al. 2000. A randomized controlled trial of prednisone in Alzheimer’s disease. Alzheimer’s Disease Cooperative Study. Neurology 54: 588–593 - PubMed
    1. Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, Jin S, Thomas RG, Thal LJ 2003. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: A randomized controlled trial. J Am Med Assoc 289: 2819–2826 - PubMed
    1. Aisen PS, Saumier D, Briand R, Laurin J, Gervais F, Tremblay P, Garceau D 2006. A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease. Neurology 67: 1757–1763 - PubMed
    1. Aisen PS, Schneider LS, Sano M, Diaz-Arrastia R, van Dyck CH, Weiner MF, Bottiglieri T, Jin S, Stokes KT, Thomas RG, et al. 2008. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: A randomized controlled trial [see comment]. J Am Med Assoc 300: 1774–1783 - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources